Redx Pharma (FRA:0RX) FCF Margin % : -851.94% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Redx Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Redx Pharma's Free Cash Flow for the six months ended in Sep. 2023 was €-18.68 Mil. Redx Pharma's Revenue for the six months ended in Sep. 2023 was €2.19 Mil. Therefore, Redx Pharma's FCF Margin % for the quarter that ended in Sep. 2023 was -851.94%.

As of today, Redx Pharma's current FCF Yield % is -59.89%.

The historical rank and industry rank for Redx Pharma's FCF Margin % or its related term are showing as below:

FRA:0RX' s FCF Margin % Range Over the Past 10 Years
Min: -13417.83 Med: -149.98 Max: 45.76
Current: -831.66

During the past 12 years, the highest FCF Margin % of Redx Pharma was 45.76%. The lowest was -13417.83%. And the median was -149.98%.

FRA:0RX's FCF Margin % is ranked worse than
73.8% of 1046 companies
in the Biotechnology industry
Industry Median: -141.025 vs FRA:0RX: -831.66

Redx Pharma FCF Margin % Historical Data

The historical data trend for Redx Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma FCF Margin % Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Margin %

Get a 7-Day Free Trial

-149.96

5.90

-220.55

-46.72

-831.52

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-129.30	29.10	-107.99	-814.69	-851.94

Competitive Comparison of Redx Pharma's FCF Margin %

For the Biotechnology subindustry, Redx Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redx Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Redx Pharma's FCF Margin % falls into.

Redx Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Redx Pharma's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-40.52	/	4.873
	=	-831.52 %

Redx Pharma's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-18.683	/	2.193
	=	-851.94 %

Redx Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Redx Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (FRA:0RX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (FRA:0RX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

REDX:UK

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (FRA:0RX) Headlines

No Headlines